STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year. The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The